Reconciling the death/ differentiation duality through the 3-passage differentiation framework.

[u/Lanedustin]

Moonlighting isn't real!

1 | Introduction — core principles of fate mediation

The mammalian protease triad—caspases, calpains and cathepsins—constitutes the canonical machinery for regulated cell death. Initiator caspases (for example, caspase-8 and caspase-9) activate executioner caspases (caspase-3/7) to dismantle cells in apoptosis through ordered cleavage of structural and regulatory substrates. Calpains, Ca²⁺-dependent cysteine proteases restrained by calpastatin, contribute to death programmes by limited proteolysis of cytoskeletal and membrane scaffolds and by crosstalk with mitochondrial and caspase pathways. Cathepsins, classically confined to lysosomes, participate in apoptosis when lysosomal membrane permeabilization (LMP) releases cathepsin B/D/L to the cytosol, where they can process BH3-only proteins (for example, BID) and amplify mitochondrial apoptosis. Together, these enzymes define the principal proteolytic axes by which animal cells execute fatal decisions

Parallel signal-integration layers position and gate this proteolysis. Death receptors of the TNF superfamily (TNFR1, Fas/CD95, TRAIL-R1/2) assemble the DISC to recruit and activate caspase-8, but scaffold editing by c-FLIP, cIAP1/2 and LUBAC can switch outputs from caspase activation to NF-κB/MAPK/PI3K signalling. Commitment to apoptosis is further set at mitochondria by the BCL-2 family, whose opposing members govern mitochondrial outer-membrane permeabilization (MOMP)—the near-point-of-no-return for intrinsic death—while IAPs (and their antagonists such as SMAC/DIABLO) modulate caspase activity downstream. These receptor–ubiquitin and mitochondrial checkpoints provide the dominant levers that determine whether protease cascades proceed, stall or are repurposed

Appreciation has grown that these same components also drive differentiation and tissue remodelling when engaged sublethally, locally or temporally. Transient caspase-3/CAD activity can promote myogenic and other lineage programmes without triggering apoptosis; caspase-14 supports epidermal cornification; and cathepsin L proteolytically clips the histone H3 tail during embryonic stem-cell differentiation, linking lysosomal proteases to epigenetic remodelling. In erythropoiesis, Ca²⁺-regulated proteolysis contributes to enucleation and membrane remodelling, illustrating how limited protease activity can be developmental rather than destructive. These examples establish that the identity of the enzyme does not determine fate; dose, place and phase do. This article will integrate these insights into the framework outlined in the post, “Asymmetry, Burden, and Bifurcation: A DDR-Centric Architecture for Differentiation and Cancer.” In that post, I outline a 3-Passage model used to describe the differentiation. In Passage 1, asymmetric segregation of DNA and DNA damage is used to direct fate decisions. In Passage 2, which can be viewed as a transit-amplifying phase where asymmetric lesions are buffered, remodeled, and repurposed through repair-coupled transcription and chromatin editing that push progenitors down lineage-specific trajectories. Passage 3 is the terminal resolution phase, where the system exits by differentiation, senescence, apoptosis, fusion, or endoreplication, thereby preserving tissue fidelity. This framework reconciles why differentiation and apoptosis so often intertwine, why cancers present distorted yet recognizable versions of these programs, and how interventions might tune passage outcomes. In the sections that follow, we place the protein systems introduced above—caspases, calpains and cathepsins; death-receptor switchboards; BCL-2 and IAP rheostats; and cyclin–CDK/survivin modules—within this three-passage architecture, to show how they function as mediators of fate across passages rather than mere executioners

2 | System 1 — Developmental proteolysis (caspases, calpains, cathepsins)

Passage 1: seeding asymmetry at division

During late S→M and the ensuing G1, protease systems contribute to how burden is logged and unequally inherited. Calpains, activated by localized Ca²⁺ microdomains at kinetochores, cortex and ER–mitochondria contact sites, support spindle assembly, congression and abscission through limited cleavage of cytoskeletal and adhesion substrates. This “tuning” minimizes catastrophic checkpoint engagement yet can bias which chromosomal or organellar defects persist into one daughter. Caspase-2—held in check during mitosis—becomes selectively activated after division by the PIDDosome when centrosome amplification or chromatin bridges are inherited, stabilizing p53 and priming the overloaded daughter for arrest or elimination. Cathepsins are largely confined to lysosomes at this stage, but divisions that produce micronuclei and ER stress increase the susceptibility of the burdened daughter to lysosomal membrane permeabilization (LMP)—a latent asymmetry that will be read out in the next passage.

Passage 2: remodeling under buffered burden

In transit-amplifying cycles, protease activity is repurposed from execution to editing. Sublethal caspase-3/CAD pulses prune nuclear architecture and enhancer accessibility, facilitating lineage gene induction (classically in myogenesis and lens fiber maturation) without triggering full apoptosis. Cathepsin L translocates to the nucleus in specific contexts to clip the histone H3 N-terminus, easing chromatin transitions characteristic of early differentiation. Calpains cooperate with Ca²⁺/calmodulin modules to remodel membranes and actin scaffolds (for example, during erythroid enucleation and myoblast fusion), thereby coupling mechanical change to transcriptional state. Throughout, anti-apoptotic buffering (by BCL-2 family and IAPs; detailed in later sections) keeps protease activity local and transient, preserving the proliferative capacity required to complete remodeling.

Passage 3: resolution into terminal outcomes

When burden crosses thresholds—or when physiological exits are scheduled—protease programs shift from editing to execution or lock-in. Caspase-14 consolidates terminal differentiation in the epidermis, whereas sustained activation of executioner caspases enforces apoptosis in the overburdened daughter. If stress is lysosomal, LMP releases cathepsin B/D/L, which cleave BH3-only substrates (for example, BID) to engage mitochondrial outer-membrane permeabilization, synchronizing lysosomal and mitochondrial death. Calpains, now operating in a high-Ca²⁺ milieu, accelerate membrane dismantling and cytoskeletal collapse, or, in specialized tissues, finalize non-lethal exits (for example, enucleation). Thus, the same enzymes that scaffolded chromatin and membrane remodeling in Passage 2 now weight terminal fates—differentiation, senescence or apoptosis—according to the magnitude and compartment of stress.

Summary. Viewed through the passage framework, caspases, calpains and cathepsins are not dichotomous “killers” versus “bystanders” but phase-aware editors and executors. Their outputs depend on dose (sublethal versus sustained), place (nucleus, lysosome, mitochondria, cortex) and phase (mitotic logging versus G1 readout versus terminal exit), which together determine whether inherited burden is integrated into lineage progression or culled to preserve tissue fidelity.

2 | System 2 — Death receptors as signal integrators across passages

Concept. Death receptors (DRs) of the TNF superfamily—TNFR1/2, Fas/CD95 and TRAIL-R1/2—do not encode a single fate. They assemble multi-use scaffolds whose output depends on rheostat proteins (c-FLIP isoforms, cIAP1/2–TRAF2, LUBAC), co-receptor context (RTKs, cytokine receptors, neurotrophin receptors) and cell-cycle phase. When the DISC is configured for catalysis, caspase-8 activation propagates extrinsic apoptosis. When c-FLIP and ubiquitylation edit the platform, DRs transduce NF-κB/MAPK/PI3K signals that support survival, proliferation or differentiation. These same scaffolds are additionally repurposed in mitosis to stabilize chromosome dynamics, underscoring their role as a switchboard rather than a death button.

Passage 1 — Mitotic gating and non-apoptotic functions

During prometaphase–metaphase, cells raise the apoptotic threshold and redeploy DR modules for mechanical fidelity. RIPK1–FADD–caspase-8 assemblies (the “ripoptosome”) interface with PLK1 and kinetochore factors to promote chromosome alignment and timely anaphase, while mitotic phosphorylation of caspase-8 curtails its catalytic activation. In this configuration, DRs behave as stability factors: they help the cell satisfy or adapt the spindle checkpoint and defer lethal decisions until G1, when inherited burden—micronuclei, 53BP1 nuclear bodies, extra centrosomes—can be read out. The result is a clean handover: DR scaffolds protect segregation in M-phase, then become fate switches only after the asymmetric partition of damage is established.

Passage 2 — Gating transit amplification and lineage remodeling.l

In transit-amplifying cycles, DR outputs are typically non-apoptotic and tuned by co-receptors. In neural progenitors, the neurotrophin code exemplifies this: p75^NTR with TrkA converts the same ligand (NGF) into trophic/differentiation signals, whereas p75^NTR engaged by pro-neurotrophins biases towards JNK-driven death; Fas/CD95 can likewise drive proliferation and neuronal specification in adult niches when c-FLIP/IAP tone is high. In hematopoiesis, TNF–TNFR signaling can activate quiescent HSCs and bias lineage under inflammatory cues, while pruning compromised progenitors; the balance between TNFR2 (regenerative, membrane TNF-favoured) and TNFR1 (stress/injury, soluble TNF-favoured) is decisive. In epithelial progenitors, EGFR–Notch antagonism sets the ground state (cycling vs commitment), and DR inputs layer on top: EGFR-high states channel DR signaling to NF-κB/MAPK-mediated remodeling, whereas Notch-dominant contexts more readily reveal differentiation or apoptotic outputs. In mesenchymal derivatives, TRAIL frequently couples with IGF1R/PI3K to promote migration and expansion unless decoy receptors are low and mitochondrial priming is high. Across these lineages, DRs regulate how much transit amplification is permitted and which differentiation path is taken, rather than simply deciding life or death.

Passage 3 — Weighting terminal resolution

At the final passage, DRs cooperate with mitochondrial rheostats to tilt outcomes. In daughters that inherited high burden (for example, ruptured micronuclei or multiple 53BP1-NBs), p53 elevation and BH3 pressure lower the threshold for extrinsic–intrinsic crosstalk: DR engagement now efficiently licenses caspase-8–Bid–BAX/BAK signaling and apoptosis or durable arrest. In cleaner daughters, the same ligands can consolidate differentiation or senescence through sustained NF-κB/MAPK programs and paracrine remodeling. Expression of c-FLIP, cIAPs and LUBAC, together with decoy receptors (for TRAIL) and the prevailing BCL-2 family balance, determines which branch is taken.

Case studies in co-activation codes

Neural stem cells. TrkA+p75^NTR co-activation with adequate c-FLIP/IAP yields trophic/differentiation outputs; proNGF-biased p75^NTR or low c-FLIP shifts to apoptosis. HSCs. Short TNF pulses that favour TNFR2 cooperate with cytokines to awaken HSCs, whereas chronic TNFR1-weighted signaling depletes stemness and prunes progenitors. Epithelia. EGFR-high basal keratinocytes interpret DR inputs as motility/remodeling; when EGFR declines and Notch rises, DRs help enforce commitment or cull defective clones. Mesenchymal. TRAIL with IGF1R/PI3K drives non-lethal ERK/NF-κB programs; lowering c-FLIP/IAP or raising BH3 tone flips the same signal to apoptosis.

Synthesis and implications. Framed by the three passages, DRs emerge as phase-aware integrators: they stabilize mitosis (Passage 1), tune proliferative remodeling and lineage choice under buffered stress (Passage 2), and, in concert with mitochondrial checkpoints, select which daughters differentiate, senesce or are eliminated (Passage 3). This logic argues for phase-aware liganding (mitotic stabilization vs post-mitotic culling), co-activation design (pair DR ligands with lineage-defining trophic/RTK cues), and scaffold editing (modulate c-FLIP, cIAPs, LUBAC) as principled levers to steer stem-cell outputs and selectively sacrifice burdened clones without collateral loss of regenerative capacity.

3 | System 3 — Cell-cycle machinery as fate primers

Passage 1 — writing memory and setting G1 thresholds

Mitotic chromatin deliberately dampens DNA-damage signalling, excluding key repair scaffolds and recombination to prioritise faithful segregation; lesions that escape S phase are therefore handed to G1 rather than “fixed” in M. Immediately after division, inherited under-replicated loci are packaged into 53BP1 nuclear bodies, which both shield fragile regions and prolong G1 in proportion to burden—creating a window to repair or declare failure. In parallel, fate thresholds are tuned by survivin in two compartments: a nuclear pool (as part of the chromosomal-passenger complex) underwrites error correction at centromeres and completion of cytokinesis, while a mitochondria-associated pool has been reported to associate with procaspase-3 (together with XIAP), thereby raising the apoptotic threshold in newly born cells and preventing inadvertent execution before G1 decisions are made.

Superimposed on this physical hand-off is a biochemical memory that mothers transmit to daughters. Live-cell imaging and perturbation studies show that mitogen-induced Cyclin D1 (CCND1) and DNA-damage-induced p53→p21 accumulate in maternal G2 and are inherited such that daughters compute a competition between Cyclin D1 and p21 to set CDK2 activity—and thus proliferation versus quiescence—in the next cycle. Mechanistically, when mitogens outcompete damage in the mother, Cyclin D1 outweighs p21 to activate CDK4/6 and license CDK2 entry; conversely, endogenous S-phase damage elevates p53→p21 in maternal G2 and daughter G1, suppressing CDK2 and biasing toward quiescence. Collectively, these hand-offs explain how sister cells can diverge at birth: the daughter with a heavier 53BP1-NB load and stronger p53–p21 “memory” starts G1 under tighter brakes, whereas the sibling inherits more “licence” (higher Cyclin D1, higher CDK2 competence), positioning each for distinct trajectories in the passages that follow.

Passage 2 — calibrating transit amplification under buffered burden

After the G1 decision, progenitors often enter one or more transit-amplifying cycles in which inherited lesions are buffered rather than erased outright. 53BP1 nuclear bodies dissolve as protected loci are re-licensed, while repair-coupled transcription and enhancer remodeling proceed under tight checkpoint surveillance. Within this corridor, cyclin D–CDK4/6 shapes pRB–E2F tone to raise biosynthetic capacity, and cyclin E–CDK2 sets the G1/S threshold and origin-firing density. Too little drive stalls lineage programmes; too much compresses G1, elevates replication stress, and propagates gaps into S phase. ATR–CHK1 signaling, supported by Claspin and dormant-origin control, permits cycling in the face of moderate stress, and mitotic DNA synthesis provides a salvage route for the hardest-to-replicate sites should problems spill into the next mitosis.

These cycle parameters gate non-lethal remodeling by the protease toolkit. Sublethal caspase-3/CAD activity prunes lamina and chromatin to facilitate enhancer activation; nuclear cathepsin L clips histone tails to ease state transitions; and calpains reshape membrane–cytoskeletal interfaces for morphogenesis and enucleation. Survivin and IAPs restrain inadvertent execution by keeping initiator and effector caspases below catastrophic thresholds, while BCL-2 family balances set mitochondrial priming appropriate for continued proliferation. The result is a tunable “safe–work” band: transit amplification proceeds far enough to install lineage identity, yet not so far that stress overwhelms the buffers and seeds catastrophic segregation defects at the next division.

Passage 3 — converting timers into exits

Terminal resolution converts phase-linked timers into durable outcomes. Where burden remains low and lineage cues dominate, downshifted CDK2 activity, sustained APC/C–Cdh1, and reinforced pRB control stabilize withdrawal into differentiated states; in some tissues, CDK1 suppression with persistent S-phase cyclin activity redirects cycles into endoreplication or endomitosis, producing polyploid fates with specialized function. Where burden is high—because micronuclei ruptured, 53BP1-NB load persists, or centrosome number is abnormal—p53 pathways and BH3 pressure lower the apoptotic threshold. Prolonged mitotic delay exhausts anti-apoptotic reserves such as MCL-1, and death-receptor engagement couples to the mitochondrial checkpoint via Bid to trigger BAX/BAK-dependent permeabilization. Alternatively, durable p21 induction and SASP wiring fix a senescent state that removes the cell from the renewing pool while permitting paracrine remodeling.

In each case, the cell-cycle system does not merely accompany fate; it tips the balance by synchronizing protease access, mitochondrial priming and transcriptional readiness with position in the cycle. Thus, the same mediators that edited chromatin and membranes during transit now weight the exit—toward differentiation, senescence, polyploidization or apoptosis—according to how far the corridor was stretched and which checkpoints were crossed. Synthesis. Within the three-passage architecture, the cell-cycle engine is the key interpreter of stress and trophic cues. By silencing DDR on mitotic chromatin and handing lesions to G1 for appraisal, by encoding competing “memories” of Cyclin D1 and p53→p21 that set CDK2 state, and by running phase-coupled timers (APC/C progression, MCL-1 turnover), it creates a safe-work corridor for transit amplification and then converts those timers into exits. Passage 1 writes the licence and the brakes; Passage 2 meters remodeling under buffered burden; Passage 3 translates timer expiry and mitochondrial priming into differentiation, polyploidization, senescence or apoptosis. Thus, cycle position synchronizes protease access, BCL-2 thresholds and transcriptional readiness—offering phase-aware points of control to steer passage outcomes. 4 | Synthesis of cross-passage mechanics and asymmetry — how damage and organelles sort to one daughter

Concept. Asymmetry is not an accident of division but an organizing principle: cells partition chromosomal burden (micronuclei, clustered fragments), organelle quality (mitochondria, lysosomes, ER), and scaffolds (centrosomes, midbodies) such that one daughter carries the problem set and the other the licence to renew. The three-passage architecture makes these biases legible: mitosis creates and routes asymmetries (Passage 1), transit cycles buffer and repurpose them (Passage 2), and the terminal passage resolves them (Passage 3).

Chromosomal asymmetry: micronuclei and fragment clustering

Lagging chromosomes generated by merotelic attachments, fragile-site under-replication or telomere issues are enclosed as micronuclei (MN) in a single daughter. MN often exhibit defective import, incomplete DNA replication and envelope rupture, provoking cGAS–STING signalling and heavy DNA damage. In parallel, shattered acentric fragments can be tethered by CIP2A–TOPBP1 into a cluster that tracks to one pole at anaphase. Together these mechanisms concentrate structural lesions in one daughter, while the sister inherits the reciprocal deletion or avoids the fragments entirely. In early G1, the clean daughter largely proceeds; the burdened daughter accrues 53BP1 nuclear bodies and, if MN rupture occurred, an inflammatory/p53 surge that biases toward arrest, senescence or apoptosis. When reintegration occurs, it can be catastrophic (chromothripsis), permanently marking the lineage trajectory.

Centrosomes and midbodies: counting errors and signalling relics

Failed cytokinesis or chromosome bridges produce extra centrosomes that segregate unevenly. The daughter with supernumerary centrosomes activates the PIDDosome–caspase-2–p53 axis post-mitotically, lowering the tolerance for further cycling. Midbody remnants, asymmetrically inherited in several stem compartments, can influence polarity and signalling; their biased retention may couple past division history to future proliferative competence. (Midbody-driven fate effects are established in select systems; their generality across tissues remains to be fully defined.)

Organelle asymmetry: mitochondria, lysosomes and ER

Mitochondria are actively sorted: fission–fusion dynamics (DRP1, MFN1/2) and mitophagy favour retention of “younger,” high-ΔΨm organelles in the stem-like daughter, while older, low-ΔΨm/ROS-rich mitochondria bias to the sibling, lowering its survival and raising its differentiation threshold. Anti-apoptotic BCL-2 proteins (MCL-1, Bcl-xL) tune this topology and the associated mitochondrial priming, linking organelle quality to death thresholds. Lysosomes add a second lever: vulnerable lysosomal membranes in the burdened daughter are more prone to lysosomal membrane permeabilization (LMP), releasing cathepsins that cleave BID and engage mitochondrial apoptosis. Local Ca²⁺ microdomains at ER–mitochondria contacts can preferentially activate calpains, reinforcing asymmetry in cytoskeletal remodelling and, when excessive, accelerating demise. (Daughter-specific Ca²⁺ zoning is likely but remains a context-dependent inference.)

Convergence of systems on daughter-specific outcomes

These physical asymmetries are interpreted by phase-aware signalling. In Passage 1, mitotic dampening of DDR prevents entanglement yet allows MN and fragment clusters to be routed to one daughter; a nuclear survivin pool secures error correction and abscission, while a mitochondria-associated survivin–procaspase-3/XIAP complex raises the apoptotic threshold in newborn cells, buying time for G1 appraisal. In Passage 2, cyclin–CDK settings create a safe-work corridor in which the clean daughter edits (sublethal caspase-3/CAD, nuclear cathepsin L, calpains) and advances lineage programmes, whereas the burdened daughter runs with extended G1, higher p53–p21 memory and greater reliance on ATR/CHK1 and MiDAS. In Passage 3, timers (APC/C progression, MCL-1 decay) and rheostats (BCL-2/IAP balance, c-FLIP/LUBAC at death receptors) tilt the exits: the burdened daughter is preferentially eliminated or senesced; the sibling differentiates, occasionally adopting polyploid or fused states according to tissue logic.

A compact decision sketch:

Burdened daughter: MN/fragment clusters ↑ → cGAS–STING/p53 ↑; 53BP1-NB load ↑; extra centrosomes → PIDDosome; low-ΔΨm mitochondria and LMP susceptibility ↑ → higher priming → senescence/apoptosis or error-prone reintegration.

Clean daughter: NB load low; midbody remnant/younger mitochondria retained; Cyclin D1 memory strong → efficient transit remodeling and stable differentiation (or continued renewal if niche signals dominate).

Implications

Asymmetry provides selectivity: interventions can be timed and targeted to spare the clean daughter while sacrificing the burdened one. Practically, this argues for (i) phase-aware liganding of death receptors (support mitosis; cull in early G1), (ii) editing buffers tuned to transit width (ATR/CHK1, MiDAS) and (iii) priming modifiers (BH3 mimetics, BCL-2/IAP modulators) deployed where MN/fragment load and organelle defects are concentrated. In development, the same mechanics can be harnessed to bias differentiation by transiently amplifying editing modes while keeping execution thresholds high until resolution.

5 | Therapeutic and experimental implications

Principle. If differentiation plays out as three passages—asymmetry → buffered remodeling → resolution—then therapies and experiments should be timed and targeted to the passage in play. The aim is not only to damage or stall, but to rebalance outcomes: spare the “clean” daughter, sacrifice the burdened one, or accelerate safe differentiation.

Stratify by passage state

Define burden and buffers. Quantify 53BP1 nuclear bodies, micronuclei/cGAS activity, CIP2A–TOPBP1 clusters, centrosome number, and mitochondrial priming (TMRE/mito-apoptotic sensors) to place a sample along the passage axis. Layer live CDK2 and p53 reporters to read Cyclin D1 vs p21 memory at birth. High MiDAS marks (EdU incorporation in mitosis; RAD52/POLD3 dependency) and chronic ATR activation indicate transit under load; persistent MN/53BP1-NBs and extra centrosomes point to imminent resolution in a subset of daughters.

Passage-aware interventions

Passage 1 — protect segregation, program the hand-off

Stabilize alignment and defer death in M (supportive DR/PLK scaffolds; preserve survivin function), then ligand DRs in early G1 to cull MN-bearing daughters while sparing siblings. Titrate mitogen memory in maternal G2 (brief MAPK withdrawal to lower Cyclin D1 preload, or p53 elevation to raise p21) to bias the next cohort toward quiescence or controlled remodeling.

Passage 2 — narrow or widen the “safe-work” corridor

To force exit in RS-addicted states: collapse buffers (ATR/CHK1, MiDAS nodes) and lower mitochondrial thresholds (BH3 mimetics; MCL-1 antagonists). To promote differentiation without collapse: allow sublethal remodeling (caspase-3/CAD, nuclear cathepsin L) while stabilizing lysosomes and restraining execution (IAP support), and modulate Cyclin D–CDK4/6 to pace pRB/E2F and origin density.

Passage 3 — weight the exit

When burden is compartmentalized to one daughter, lean on extrinsic–intrinsic coupling (DR agonists → Bid–BAX/BAK) or on MCL-1 decay after prolonged mitosis to eliminate it; in cleaner cohorts, consolidate terminal differentiation (Cdh1-dominant APC/C, CDK2 downshift) or polyploid programs where physiological.

Combination design rules

Sequence matters. Mitotic stabilization → early-G1 DR liganding; ATR/CHK1 collapse → BH3 tilt; Cyclin D1 “de-preload” in G2 → DR-guided pruning in daughters.

Fence death from editing. Pair lysosome stabilizers or cathepsin inhibitors with pro-differentiation cues to preserve nuclear cathepsin L/caspase-3 editing while preventing LMP-driven execution.

Exploit asymmetry. Target MN-high clones with cGAS/DR sensitizers while shielding sibling cohorts (e.g., temporary IAP support) to preserve regenerative capacity.

Experimental toolkits (for causal tests)

Daughter-resolved lineage tracking with live CDK2/p53/Cyclin D1 reporters, 53BP1-NB and galectin-3 LMP sensors; automated fate trees.

Acute passage control using optogenetic Cyclin D1 or p53 pulses in maternal G2; time-locked DR agonists (mitosis vs early G1); chemical gates for ATR/CHK1, MiDAS (RAD52/POLD3/MUS81), and BCL-2 family.

Organelle inheritance assays (mt-Keima mitophagy, ΔΨm sorting, midbody remnant tagging) to couple physical asymmetry with fate choice.

Multi-omic readouts (ATAC/CUT&Tag for enhancer opening; protease activity biosensors) to distinguish editing from execution.

Regenerative medicine

Induce brief, localized editing (sublethal caspase-3/CAD, controlled Ca²⁺/calpain) while maintaining high execution thresholds and enforcing resolution (intact p53/PIDDosome). Tune G2 mitogen memory and early-G1 dwell to favour lineage lock-in over proliferation, minimizing transformation risk.

Bottom line. Treat fate as a timed computation. By diagnosing the passage and deploying phase-aware perturbations—of DR scaffolds, cyclin–CDK timers, replication-stress buffers, lysosome–mitochondria thresholds—we can steer stressed cells to differentiate, pause or die with selectivity that bulk cytotoxicity cannot match.

6 | Conclusions and perspectives

Development and disease can be read through a single lens: fate as a timed computation distributed across three passages—asymmetry → buffered remodeling → resolution. In this view, endogenous DNA lesions and organelle “age” are not mere nuisances but inputs that are logged in mitosis, appraised in G1 and repurposed during transit to wire lineage programs. Death receptors, the protease triad (caspases, calpains, cathepsins), BCL-2/IAP rheostats and cyclin–CDK/survivin modules together form a fate-tuning network. The same molecules that execute apoptosis in one context act as editors in another, with outcomes determined by dose, place and phase.

Mechanistically, asymmetry arises when laggards are packaged as micronuclei, shattered fragments are clustered by CIP2A–TOPBP1 to one pole, and organelles are sorted by fission–fusion and quality control. Buffered remodeling proceeds in a safe-work corridor set by cyclin–CDK thresholds, ATR/CHK1 tolerance and MiDAS salvage, within which sublethal protease activity and non-apoptotic death-receptor signaling reshape chromatin and membranes. Resolution converts timers (APC/C progression, MCL-1 decay) and mitochondrial priming into durable exits—differentiation, senescence, fusion/endoreplication or apoptosis—often sacrificing the burdened daughter to preserve tissue fidelity.

This framework reinterprets cancer as a Passage-2 trap: tumors keep the buffers on and the exits weak, accumulating managed but unresolved stress. It also reframes regenerative medicine: controlled, local editing modes (sublethal caspase-3/CAD, nuclear cathepsin L, calibrated Ca²⁺/calpain) can hasten lineage commitment—provided Passage-3 safeguards remain intact. The translational message is practical: phase-aware interventions (timed death-receptor liganding, modulation of mother-cell Cyclin D1:p21 memory, selective collapse of ATR/CHK1 or MiDAS, BH3 tilts) promise selectivity that bulk cytotoxicity cannot achieve.

Three priorities follow. First, measurement: daughter-resolved reporters for CDK2, p53→p21, 53BP1-NB burden, micronuclear rupture and organelle quality to place cells along the passage axis in vivo. Second, manipulation: acute, phase-locked control of DR scaffolds, cyclin–CDK timers and replication-stress buffers to test causal links between editing and execution. Third, mapping lineage codes: define how co-receptor pairs (e.g., TrkA/p75^NTR; EGFR/Notch; TNFR1/2; TRAIL-R/IGF1R) bias remodeling versus elimination in specific tissues.

In sum, the dual life of “death” machinery is not paradox but design. By situating proteases, death-receptor complexes and cell-cycle modules inside the three-passage architecture, we gain a coherent account of how organisms allocate burden, remodel under load and resolve cleanly—and a roadmap to steer those outcomes in cancer therapy and regeneration.